Fortress Biotech, Inc. (NASDAQ:FBIO - Free Report) - Equities researchers at HC Wainwright issued their Q4 2026 earnings per share (EPS) estimates for shares of Fortress Biotech in a report released on Tuesday, November 17th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings per share of ($0.15) for the quarter.
Fortress Biotech (NASDAQ:FBIO - Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.04. Fortress Biotech had a return on equity of 61.84% and a net margin of 143.04%. The company had revenue of $19.16 million during the quarter, compared to analyst estimates of $21.57 million.
Several other equities analysts also recently weighed in on FBIO. Wall Street Zen downgraded shares of Fortress Biotech from a "strong-buy" rating to a "hold" rating in a research note on Saturday, August 15th. Weiss Ratings lowered shares of Fortress Biotech from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, October 23rd. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $17.00.
View Our Latest Stock Report on FBIO
Fortress Biotech Price Performance
NASDAQ FBIO opened at $1.82 on Wednesday. The company has a quick ratio of 3.83, a current ratio of 2.93 and a debt-to-equity ratio of 0.10. The company has a market cap of $61.41 million, a PE ratio of 0.79 and a beta of 1.27. Fortress Biotech has a 52 week low of $1.64 and a 52 week high of $4.53. The firm's 50-day simple moving average is $2.10 and its two-hundred day simple moving average is $2.71.
Hedge Funds Weigh In On Fortress Biotech
A number of large investors have recently made changes to their positions in the stock. Marshall Wace LLP bought a new stake in shares of Fortress Biotech during the 3rd quarter valued at $462,000. Renaissance Technologies LLC lifted its holdings in Fortress Biotech by 22.8% during the 1st quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company's stock worth $278,000 after purchasing an additional 18,490 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in Fortress Biotech during the 2nd quarter worth about $47,000. 96.51% of the stock is owned by institutional investors.
About Fortress Biotech
(
Get Free Report)
Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company's activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fortress Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortress Biotech wasn't on the list.
While Fortress Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.